If the year 2011 was the year for the 5% of skin cancers, this is the year for the 95% majority. Last year saw approvals of two new melanoma cancer drugs, vemurafenib and ipilimumab. But, this year may be dubbed as the year when the other skin cancer called basal cell carcinoma finally gets a new Erivedge loaded Webley.
Skin cancer is the most common type of
cancer in the western world—40% of all cancers are skin cancers with 80% of skin cancers being
nonmelanoma, and primarily basal cell carcinoma.
